The antigen KOR-SA3544 is physiologically expressed exclusively on granulocytes. Aberrant expression of KOR-SA3544 has been invariably found in BCR/ABL-positive acute lymphoblastic leukemia (ALL) and in some BCR/ABL-negative ALL. In an interim analysis of a prospective clinical and cytometric study data of 73 children with newly diagnosed or relapsed ALL with and without TEL/AML1 fusion are presented. KOR-SA3544 expression over 3% was detected in the majority of TEL/AML1-negative patients with newly diagnosed common or preB ALL (19 of 31) and not in TEL/AML1-positive patients (0 of 18, P Ͻ 0.0001). The level of expression of KOR-SA3544 was 0.02-90% (median 6.0%) and 0.03-2.4% (median 0.23%) in TEL/AML1-negative and TEL/AML1-positive patients, respectively. All five newly diagnosed patients with DNA index у1.16 and Ͻ1.6 exhibited high levels of KOR-SA3544 expression. Membrane expression of CD79a was found to correlate with TEL/AML1 negativity, although less significantly than KOR-SA3544 (P = 0.03). Furthermore, our data confirm that TEL/AML1 positivity correlates with non-hyperdiploidy and low presenting age. In conclusion, KOR-SA3544 correlated strongly with TEL/AML1 negativity, it was a better predictor of TEL/AML1 status than other factors tested and was found at high levels in hyperdiploidy. In combination with age, KOR-SA3544 predicted TEL/AML1 status in 86% newly diagnosed preB/cALL patients.
Introduction
KOR-SA3544 antigen is a glycoprotein of molecular mass 80-100 kDa which is expressed on the surface of normal granulocytes. 1 The KOR-SA3544 monoclonal antibody (MAb) was generated by Mori et al 1 using a cell line from congenital myelomonocytic leukemia. Among acute lymphoblastic leukemia (ALL) blasts, KOR-SA3544 MAb has been found to react with all BCR/ABL-positive cases, albeit non exclusively -in a pilot study, positivity of over 30% blasts was found in 13% of common ALL (cALL) and in 5% proB ALL patients. 1 The reciprocal translocation t(12;21) resulting in the fusion of genes TEL (synonym ETV6) and AML1 (synonym CBF␣), is currently considered the most frequent chromosomal abnormality in childhood ALL. 2, 3 The majority of children with TEL/AML1-positive ALL are aged 1 to 5 years 4 and are reported to have an excellent outcome. 3 The prevalent immunophenotypes of TEL/AML1-positive ALL are common ALL and preB ALL and most cases are euploid. 4 The TEL/AML1 positivity was found to correlate with co-expression of myeloid antigens. 4, 5 In this report, we compare the immunophenotype of 73 unselected children with newly diagnosed or relapsed ALL. We show a strong inverse correlation between TEL/AML1 positivity and KOR-SA3544 antigen positivity which appears to 
Materials and methods

Patients
Bone marrow (BM) and/or peripheral blood (PB) samples were available between April 1997 and February 1998 for 77 unselected newly diagnosed or relapsed patients with ALL younger than 18 years. All 77 patients whose specimens were sent to our laboratory during the study period were considered for entry. A total of four patients were excluded: specimens of two patients were considered unrepresentative as they did not contain a distinct blast population; one specimen of a relapsed patient froze accidentally during transportation and one specimen could not be tested for KOR-SA3544 due to low sample volume. Further data refer to 73 patients (Table 1) . Samples of all patients were successfully analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) for the presence of fusion genes TEL/AML1, MLL/AF4 and BCR/ABL. All patients were treated according to ALL BFM 90 or 95 protocols (excluding four infants treated according to POG protocol No. 9407) in one of the Pediatric Hematology Working Group centers. Throughout this study, age 1 refers to age у1 year and Ͻ2 years at diagnosis and correspondingly in all other age groups.
RT-PCR amplification and analysis of RT-PCR products
Total RNA was extracted from cryopreserved BM or PB cells using the modified method described by Chomczynski and Sacchi. 6 The integrity and quantity of extracted RNA was esti- mated on ethidium bromide-stained non-denaturating agarose gel. Complementary DNA was prepared using MMLV Reverse Transcriptase (Gibco BRL, Eggenstein, Germany) under conditions recommended by the manufacturer. The one-step amplification of ABL exons a2/a3 was used as a cDNA quality control. The sequences of these primers were: A2 5Ј-TTCAGCGGC-CAGTAGCATCTGACTT-3Ј and A3 5Ј-TGTGATTATAGCCT-AAGACCCGGAGCTTTT-3Ј. For the detection of TEL/AML1 transcript, primers used in the first amplification step were: TL667 5Ј-GCTGAGAGA GCTCA GGGACC-3Ј and AM1130 5Ј-ATCTTGCCTGGGCTCAGCGC-3Ј. PCR products from the first round were then diluted 100× and subsequently used in the second-step amplification with primers TL841 5Ј-ATCATGCACCCTCTGATCC-3Ј and AM1109 5Ј-GTGGAAGGCGGCGTGAAGC-3Ј. The amplification profile on a DNA thermal cycler (Perkin Elmer 9600/2400, Norwalk, CT, USA) was as follows: denaturation at 95°C for 3 min, then 40 cycles of 30 s at 94°C, 20 s at 63°C, 40 s at 72°C, with a 10-min final extension at 72°C. The RT-PCR products were analyzed on ethidium bromide-stained aragose gel. Sensitivity of RT-PCR was assessed by dilution of cells from a TEL/AML1-positive patient into blood cells of a healthy volunteer donor ( Figure 1 ). Specificity of the products was confirmed by hybridization with digoxigenin-labeled probe and by direct sequencing.
In addition, all patients were routinely examined for the presence of MLL/AF4 and BCR/ABL fusion genes using RT-PCR.
Cytometry evaluation
Bone marrow aspirate and/or peripheral blood from all patients was analyzed using flow cytometry at diagnosis or relapse. All specimens were analyzed in a single laboratory using dual-color cytometry. Specimens were collected in polypropylene tubes with ethylene diamine tetraacetic acid (EDTA). Cell number was determined using light microscopy and diluted to 4 × 10 7 per ml with 1% bovine serum albumin (Sevac, Praha, Czech Republic) in phosphate-buffered saline (PBS, pH 7.2-7.4) when necessary. Specimens containing up to 10 5 cells were then incubated in combinations of MAbs labeled with phycoerythrin (PE) or fluorescein isothiocyanate (FITC) for 15 min in the dark at room temperature. The panel of MAbs included fluorochrome-labeled MAbs to all antigens 
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+ cells were monitored in all cases with B lineage ALL. After incubation with MAbs, erythrocytes were lysed with NH 4 Cl-containing lysing solution (containing NH 4 Cl 0.16 M, NaHCO 3 12 mM, EDTA 0.13 mM, NaN 3 0.02%, pH adjusted to 7.2-7.4) and centrifuged. Specimens were subsequently washed and resuspended in PBS and analyzed within 2 h using dual-color cytometry in FACS Calibur flow cytometer (Becton Dickinson). Analysis was performed using CellQuest software as follows: blast cells were chosen based on the light scatter plot and validated by antibody staining; care was taken to keep all non-malignant cells that were distinguishable by light scatter out of the blast gate. Standard cutoff point for positivity of antigens was set at 20% of gated blasts. Usage of different cutoff points is always mentioned in the text. The immunophenotype analysis was always performed prior to molecular genetic results and none of the results was re-analyzed or omitted after the molecular genetic classification to avoid possible bias. The immunological categorization of ALL was performed as described by the EGIL group. 7 For patients with aberrant antigens, the scoring system for the definition of biphenotypic ALL was used;
7 patients with biphenotypic ALL were included in the respective category based on lymphoid antigens. For intracellular staining, a simple permeabilizing technique by FACS Lysing Solution (Becton Dickinson) was used as described by Tiirikainen. 8 Cytometric DNA analysis
The Cycle Test Plus DNA Reagent kit (Becton Dickinson) was used according to the manufacturer's recommendation. Briefly, cell suspension was resuspended in trypsin-and spermine tetrahydrochloride-containing buffer and subsequently in ribonuclease A-and trypsin inhibitor-containing buffer followed by propidium iodine staining at room temperature. The DNA contents were then acquired in a doubletdiscrimination mode using FACS-Calibur flow cytometer (Becton Dickinson) and analyzed with CellQuest (Becton Dickinson) and ModFit (Verity House, Topsham, ME, USA) software applications. DNA index represents the position of the aneuploid peak vs the euploid peak; samples without aneuploidy are shown as having DNA index 1.00.
Statistical analysis
The expression of KOR-SA3544 was compared between hyperdiploid and non-hyperdiploid patients using the Mann-Whitney U test. Fisher's exact test of the 2 × 2 contingency tables was used to assess significance of correlations elsewhere throughout the study.
Results
Immunophenotype subgroups and presence of gene fusions
As shown in Table 1 , the majority of children had common ALL (cALL) or preB ALL -the subgroup of cALL/preB ALL patients represented 75 and 88% of newly diagnosed and relapsed ALL patients, respectively. Eighteen newly diagnosed patients (37% of cALL/preB ALL patients) had TEL/AML1-positive blasts. In addition, two relapsed patients exhibited TEL/AML1 positivity and two infants with proB ALL had MLL/AF4 fusion ( Table 1) . One patient with newly diagnosed preB ALL was BCR/ABL-positive. A total of five patients was scored as having acute hybrid leukemia: newly diagnosed proB ALL/myeloid (n = 3), newly diagnosed preB ALL/myeloid (n = 1) and relapsed cALL/myeloid (n = 1). These patients are included in the respective category based on the lymphoid antigens.
Immunophenotype classification and presence of KOR-SA3544-positive blasts As described below, the optimal cutoff value to show the presence of KOR-SA3544-positive cells was set at 3% in the blast gate. As shown in Table 1 , KOR-SA3544-positive blasts above 3% were detected in 24 patients. Twenty-three of these patients belonged to the cALL/preB ALL group and one patient had acute hybrid leukemia of proB ALL/myeloid phenotype (however, she had only 3.4% KOR-SA3544-positive cells in a gate, Figure 2 ). Both MLL/AF4-positive patients with proB ALL were KOR-SA3544-negative. The patient with BCR/ABL-positive preB ALL had high expression of KOR-SA3544 (90%, Figure 3) . Typical patterns of fluorescence in KOR-SA3544-high, -low and -negative samples are shown in Figure 2 .
Correlation of age at presentation, DNA content and immunophenotype with TEL/AML1 status in newly diagnosed cALL/preB ALL All antigens assessed in addition to age at presentation were evaluated for correlation with TEL/AML1 positivity. As shown in Table 2 , TEL/AML1 positivity was found to correlate significantly with KOR-SA3544 negativity (also in Figure 3 ), membrane negativity of CD79a, age 2-4 years at diagnosis and combined criteria. Each of the myeloid antigens CD13 and CD33 were found in a larger fraction of TEL/AML1-positive patients than among TEL/AML1-negative patients (Table  2) . However, the difference did not reach significance even if a combination of the two antigens was tested as a predictive criterion.
High predictive value of KOR-SA3544 for TEL/AML1 negativity prompted us to search for additional criteria that may increase the predictive value for TEL/AML1 positivity. We analyzed KOR-SA3544 positivity in combinations of either immunopehnotype or clinical features (the tested criteria were combined using logical and or logical or). Although some of the combinations that use logical and did correlate with TEL/AML1 status (Table 2) , their predictive values were lower than that of KOR-SA3544 positivity alone (Table 2 , other data not shown). The other possible approach that may increase positive predictive value is to combine KOR-SA3544 positivity or a secondary criterion predictive for TEL/AML1 negativity. In this type of analysis, non-peak presenting age (i.e. Ͻ1 or Ͼ5 years at diagnosis) and negativity of CD33 (but not CD13 negativity) appeared useful as secondary criteria in our cohort (Table 3) . Among 30 newly diagnosed KOR-SA-negative patients with cALL or preB ALL, 17 were of peak age (14 of these 17 patients were TEL/AML1-positive) and 13 patients were of non-peak age (four of these 13 were TEL/AML1-positive).
Correlation of TEL/AML1, KOR-SA3544 and DNA ploidy in cALL/preB ALL patients DNA ploidy was examined in 42 newly diagnosed patients with cALL or preB ALL. Among these patients, hyperdiploidy у1.16 and Ͻ1.6 was found exclusively in TEL/AML1-negative patients. Therefore, we also tested whether these hyperdiploid patients were more likely to be KOR-SA3544-positive. As shown in Figure 4 , all five hyperdiploid patients (with DNA index у1.16 and Ͻ1.6) were KOR-SA3544 highly positive. One TEL/AML1-positive patient had DNA index 1.12 together with negative KOR-SA3544 expression (Figure 4) . The higher KOR-SA3544 expression in patients with DNA index у1.16 and Ͻ1.6 was statistically significant (P = 0.004). However, one TEL/AML1-positive relapsed patient had hyperdiploidy with DNA index 1.38 and negative KOR-SA3544 expression (0.47%). In contrast, four of five euploid relapsed patients had high KOR-SA3544 expression. When newly diagnosed and relapsed cALL/preB ALL patients were tested together, the difference in KOR-SA3544 expression between hyperdiploid and non-hyperdiploid patients was not significant (P = 0.096).
Discussion
In the present study, we compared immunophenotype with the presence or absence of TEL/AML1 fusion transcript in 73 consecutive children with ALL. We found that positivity of both KOR-SA3544 and TEL/AML1 were limited to BCP ALL patients. Confinement of TEL/AML1-positive ALL to BCP ALL subgroup is in agreement with earlier observations. 4 Moreover, we found that aberrant expression of KOR-SA3544 in over 3% blasts at diagnosis unexceptionally predicted TEL/AML1 negativity. In the original report by Mori et al, 1 the presence of KOR-SA3544 was described as a constant feature of BCR/ABL-positive ALL and in a fraction of BCR/ABL-negative patients. As shown here, the presence of the small proportion of KOR-SA3544-positive cells indicates TEL/AML1 negativity of the whole blast population of a particular patient. Therefore, the ability to synthesize and express the KOR-SA3544 antigen in a blast subset rather than the KOR-SA3544 expression per se seems to be the biological factor that correlates with TEL/AML1 negativity of a particular cell. However, further studies will be necessary to clarify biological properties of blast subsets expressing the KOR-SA3544 antigen. Other molecular-genetic properties have also been found to correlate with the existence of a minor aberrant expression such as BCR/ABL positivity and higher CD25 expression.
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In contrast to the KOR-SA3544 antigen, aberrant expression of some of the other myeloid antigens has previously been
Figure 2
Representative examples of KOR-SA3544 expression by leukemia blasts. All dot plots show expression of CD19 and KOR-SA3544 on blasts gated by light scatter properties. Upper row shows typical patterns of KOR-SA3544 expression in TEL/AML1 negative cALL/preB ALL patients; from left to right, high, medium and no KOR-SA3544 expression is shown. Lower row shows the only proB ALL specimen with aberrant expression over 3% gated blasts (left); highest KOR-SA3544 expression among the TEL/AML1-positive patients (2.4%, middle); and a typical pattern in T lineage ALL with no KOR-SA3544 expression (right).
Figure 3
The KOR-SA3544 antigen expression on blasts of patients newly diagnosed with cALL or preB ALL. Patients are divided according to the presence of TEL/AML1 fusion. Numbers represent percentage of co-expression of CD19 and KOR-SA3544. Horizontal line shows the cutoff value at 3%. Triangles represent KOR-SA3544 expression in a BCR/ABL-positive patient.
described to correlate with TEL/AML1 positivity. 4, 5 These include CD13, CD33 and CD65. 4, 5 None of these antigens by themselves, nor combinations of them, were found to correlate significantly in this study. However, when we analyzed all newly diagnosed cALL/preB ALL patients tested in our laboratory in the period from September 1996 to March 1997 together with patients included into this study, CD33 positivity correlated significantly with TEL/AML1 positivity among newly diagnosed cALL/preB ALL patients (n = 63, P = 0.006, data not shown). Although we showed the tendency of CD13 to be expressed predominantly in TEL/AML1-positive patients, this difference was not significant and we also did not observe a significant correlation between CD13 and TEL/AML1 positivity in patients between September 1996 and February 1998 (data not shown). In contrast to CD33 and CD13, aberrant expression of myeloid antigens CD15 and CD65 appeared to provide no additional information relevant to TEL/AML1 prediction in our cohort. The expression of myeloid antigens by ALL blasts is speculated to reflect either lineage infidelity due to aberrant gene expression, neoplastic transformation of rare bilineage lymphoid/myeloid progenitor cells, or transformation of a multipotent lymphohematopoietic precursor cell. [10] [11] [12] [13] [14] However, aberrant expression of myeloid antigens (including CD33) is frequently found in adults, 10, 15 in whom TEL/AML1 is a rare phenomenon. 16 Importantly, prospective and casecontrol studies have documented favorable prognosis of TEL/AML1-positive children 3, 17 whereas myeloid antigen expression has recently been found to have no impact on prognosis in a large prospective study. 10 The aberrant expression of antigens CD33, CD13 and perhaps CD65 therefore seems to occur in a yet undefined subgroup of ALL, into which most of TEL/AML1-positive patients belong. Apart from myeloid antigens, some B cell differentiation antigens may be important as was shown by the Pediatric Oncology Group study. 18 In their study, negativity or partly positive expression of CD9 and CD20 antigens correlated with TEL/AML1 positivity. However, details of this study including the cutoff values are not yet available. Our data show a tendency of TEL/AML1-positive children to be CD20-negative, although the difference was not significant. Another important B cell differentiation antigen, surface CD79a, was found to correlate with TEL/AML1 negativity in our study.
Several immunophenotypes potentially valuable for the TEL/AML1 status prediction have been suggested. 4, 5, 18 All of these suggested TEL/AML1-predictive immunophenotypes use combinations of results for more than one antigen as a predictive criterion. Thus, KOR-SA3544 may be a valuable indicator as it has a strong specificity by itself and may distinguish patients with a high likelihood of being TEL/AML1-negative. Studies in larger cohorts will be useful to prove or disprove the exclusiveness of KOR-SA3544 expression in TEL/AML1-negative patients. Aberrant expression of KOR-SA3544 significantly correlated with hyperdiploidy in the present study. Importantly, one of the relapsed TEL/AML1-positive patients had hyperdiploidy and not KOR-SA3544 aberrant expression. It has been reported previously that TEL/AML1 positivity in hyperdiploid cases is a rare but documented phenomenon. 4 Although there were too few patients to allow detailed analysis of the relationship between hyperdiploidy, KOR-SA3544 and TEL/AML1 status, it may be concluded that the KOR-SA3544 + and hyperdiploid subgroups are not mutually exclusive and that KOR-SA3544 positivity may be a more sensitive indicator of TEL/AML1 negativity than hyperdiploidy.
Our data show that a positive result of KOR-SA3544 expression has a very high predictive value (100% in our cohort). However, a negative result has a predictive value of only 60%. In comparison, expression of other myeloid antigens (CD13 Ͼ10% or CD33 Ͼ10% in the study of Baruchel et al, 5 or two of the antigens CD13, CD33 and CD65 higher than 20% reported by Borkhardt et al 4 ) had a predictive value of 64% and 71% for TEL/AML1 positivity; the predictive values of negative tests for TEL/AML1 negativity were 89% and 81% (recalculation of data in Refs 5 and 4, respectively). Aneuploidy with DNA index 1.16 to 1.6 predicts TEL/AML1 negativity, 4 similarly as does KOR-SA3544 expression. The predictive value of hyperdiploidy (у1.16 and Ͻ1.6) for TEL/AML1 negativity was 96% in a larger study. 4 In our cohort, five of five newly diagnosed patients with DNA index 1.16 to 1.6 were TEL/AML1-negative whereas one relapsed KOR-SA3544-negative patient with DNA index 1.38 was TEL/AML1-positive. Although larger studies may prove hyperdiploidy and KOR-SA3544 positivity to have comparable prognostic values for TEL/AML1 negativity, aberrant expression of KOR-SA3544 antigen is found more frequently than hyperdiploidy. Therefore, it may provide predictive information in a larger fraction of patients.
The overall prognostic values (ie 100× (true positive + true negative)/total cases) of the previously reported relevant immunophenotype tests ranged from 75 to 83%. 4, 5, 18 The overall prognostic value of KOR-SA3544 in our cohort was 76% and 86% for the antigen alone and for antigen combined with age, respectively. If these percentages are proven in larger cohorts, combination of KOR-SA3544 as a major criterion and age as an additional criterion could predict both negativity and positivity of TEL/AML1 fusion with higher predictive value than other immunophenotypic features.
Immunophenotypic prediction of TEL/AML1 status has been considered to have a potential effect on the cost-effectiveness of TEL/AML1 investigation. 18 However, we feel that TEL/AML1 investigation should be performed in all children at this point. One reason is that the favorable prognostic impact of TEL/AML1 positivity has recently been questioned 19 and the true value of TEL/AML1 may be difficult to ascertain without all children being evaluated. Moreover, the economic impact of TEL/AML1 pre-screening would be questionable since all patients have to be tested for BCR/ABL fusion and cDNA is therefore available for TEL/AML1 detection.
The KOR-SA3544 due to its strict negativity in physiologic lymphoid cells is a valuable marker for the detection of minimal residual disease. 1 It is a very sensitive marker for detection of a minor subset of ALL patients with BCR/ABL positivity. 1 As shown here, it may be valuable for defining differences between patients with or without the TEL/AML1 fusion. Thus, more data on structural and functional features of the KOR-SA3544 glycoprotein may elucidate some of the biological properties of childhood ALL. The predictive value of KOR-SA3544 testing for TEL/AML1 status is shown to be comparable or superior to previously reported clinical and laboratory predictive features.
